Displaying drugs 7676 - 7700 of 8236 in total
Pateclizumab
Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis).
Investigational
Matched Description: … Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of …
Efinopegdutide
Efinopegdutide is under investigation in clinical trial NCT03606057 (A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)).
Investigational
Matched Description: … Efinopegdutide is under investigation in clinical trial NCT03606057 (A Study to Investigate the Effect of …
GX-19 Vaccine
The GX-19 vaccine is a DNA vaccine created by Genexine, Inc. Company in Gyeonggi, Korea . As of June 2020, the vaccine candidate is undergoing Phase I and Phase IIa trials to determine dose levels for safety and efficacy[A219758,L16488].
Investigational
Matched Description: … As of June 2020, the vaccine candidate is undergoing Phase I and Phase IIa trials to determine dose levels …
Gavocabtagene autoleucel
Gavocabtagene autoleucel is a novel cell therapy consisting of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex.
Investigational
Matched Description: … Gavocabtagene autoleucel is a novel cell therapy consisting of autologous genetically engineered T cells …
D2C7 immunotoxin
D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the Pseudomonas exotoxin, PE38-KDEL. D2C7-IT is under investigation in clinical trial NCT04160494 (D2C7-IT With Atezolizumab for Recurrent Gliomas).
Investigational
Matched Description: … dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of …
Livmoniplimab
Livmoniplimab is under investigation in clinical trial NCT06109272 (A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)).
Investigational
Matched Description: … clinical trial NCT06109272 (A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of …
Cyanamide
A cyanide compound which has been used as a fertilizer, defoliant and in many manufacturing processes. It often occurs as the calcium salt, sometimes also referred to as cyanamide. The citrated calcium salt is used in the treatment of alcoholism. [PubChem]
Experimental
Matched Description: … The citrated calcium salt is used in the treatment of alcoholism. [PubChem] …
D-Asparagine
A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from ASPARTIC ACID and AMMONIA by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed)
Experimental
Matched Description: … A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain …
LY2275796
LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development. LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases.
Investigational
Matched Description: … LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of …
ATG-Fresenius S
ATG-Fresenius S is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line. ATG-Fresenius S is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation.
Investigational
Matched Description: … ATG-Fresenius S is an immunosuppressive product for the prevention and treatment of acute rejection following …
(Z)-2-[2-(4-methylpiperazin-1-yl)benzyl]diazenecarbothioamide
(Z)-2-[2-(4-methylpiperazin-1-yl)benzyl]diazenecarbothioamide is a solid. This compound belongs to the phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group. This drug targets the protein S100B.
Experimental
Matched Description: … These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a …
Methylmethionine chloride
Methylmethionine chloride may be useful in helping the healing of gastric ulcers. In Japan, it is used as an over the counter product for gastrointestinal health support. It is also called "Vitamin U", but it is not a true vitamin.
Experimental
Matched Description: … Methylmethionine chloride may be useful in helping the healing of gastric ulcers. …
SR-9009
SR-9009 is a REV-ERB agonist. SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues .
Experimental
Matched Description: … and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of …
SR-9011
SR-9011 is a REV-ERB agonist. SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues .
Experimental
Matched Description: … and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of …
Uprifosbuvir
Uprifosbuvir is under investigation in clinical trial NCT02332707 (Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)).
Investigational
Matched Description: … Uprifosbuvir is under investigation in clinical trial NCT02332707 (Efficacy and Safety of Grazoprevir …
Inavolisib
Inavolisib (GDC-0077) is under investigation in clinical trial NCT03006172 (To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer).
Investigational
Matched Description: … investigation in clinical trial NCT03006172 (To Evaluate the Safety, Tolerability, and Pharmacokinetics of …
Cinaciguat
Cinaciguat is under investigation in clinical trial NCT01067859 (A Phase Iib Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 ΜG/h, 10 ΜG/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)).
Investigational
Matched Description: … investigation in clinical trial NCT01067859 (A Phase Iib Study to Investigate the Efficacy and Tolerability of …
FF-10501-01
FF-10501-01 is a novel, selective inosine monophosphate dehydrogenase (IMPDH) inhibitor with anticancer activity. FF-10501-01 is under investigation in clinical trial NCT03486353 (A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome).
Investigational
Matched Description: … [A257306] FF-10501-01 is under investigation in clinical trial NCT03486353 (A Study of FF-10501-01 in …
SS1(dsFv)-PE38
SS1(dsFv)-PE38 is a recombinant anti-mesothelin immunotoxin. SS1(dsFv)-PE38 is under investigation in clinical trial NCT01051934 (A Phase I Trial of SS1 (Dsfv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-small Cell Lung Adenocarcinoma).
Investigational
Matched Description: … SS1(dsFv)-PE38 is under investigation in clinical trial NCT01051934 (A Phase I Trial of SS1 (Dsfv) PE38 …
Elacytarabine
Elacytarabine is a fatty acid derivative of cytarabine, an approved cytotoxic cancer drug. Cytarabine has limitations such as minimal uptake in solid tumours and is only used to treat leukaemia. Elacytarabine is designed to overcome this limitation and has shown considerable uptake in solid tumour cells. Elacytarabine is a patented...
Investigational
Matched Description: … Elacytarabine is a fatty acid derivative of [cytarabine], an approved cytotoxic cancer drug. ... Elacytarabine is a patented new chemical entity of the nucleoside analog class, with improved biological …
KBP-COVID-19
The KBP-201 COVID-19 Vaccine was developed by British American Tobacco’s (BAT) U.S. biotech subsidiary, Kentucky BioProcessing (KBP). KBP cloned COVID-19’s genetic sequence, identified a potential antigen, and then inserted it into tobacco plants for reproduction. Upon harvest, the antigens were purified, and these components underwent preclinical testing in animals. As...
Investigational
Matched Description: … of KBP-COVID-19 vaccine in healthy patients (NCT04473690). ... As of July 2020, KBP is conducting a Phase 1/2 clinical trial to evaluate the safety and immunogenicity …
Cyclohexanol
Monohydroxy derivatives of cyclohexanes that contain the general formula R-C6H11O. They have a camphorlike odor and are used in making soaps, insecticides, germicides, dry cleaning, and plasticizers. [PubChem]
Experimental
Matched Description: … Monohydroxy derivatives of cyclohexanes that contain the general formula R-C6H11O. …
AT9283
AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer. It was discovered and developed internally using Astex’s fragment-based drug discovery platform, Pyramid.
Investigational
Matched Description: … AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer. …
MLN-977
MLN-977 is a small molecule compound that inhibits the production of leukotrienes, especially 5-lipoxygenase. It is developed by PharmaEngine to treat asthma and chronic obstructive pulmonary disease.
Investigational
Matched Description: … MLN-977 is a small molecule compound that inhibits the production of leukotrienes, especially 5-lipoxygenase …
TNX-901
TNX-901 is a therapeutic monoclonal antibodies designed to address significant unmet medical needs in the areas of asthma, allergy, inflammation and other diseases affecting the human immune system.
Investigational
Matched Description: … therapeutic monoclonal antibodies designed to address significant unmet medical needs in the areas of …
Displaying drugs 7676 - 7700 of 8236 in total